证券代码：301408 证券简称：华人健康 公告编号：2026-006 安徽华人健康医药股份有限公司 关于公司股东部分股份解除质押的公告 股东名称 是否为控股 股东或第一 大股东及其 一致行动人 本次解除质 押股份数量 （万股） 占其所持 股份比例 占公司总 股本比例 起始日 解除日期 质权人 合肥时达股权 投资合伙企业 （有限合伙） 否 175 49.0177% 0.4375% 2024 年 4 月 29 日 2026 年 3 月 2 日 颜牡丹 一、本次解除质押的基本情况 三、其他说明 1、截至本公告披露日，股东时达投资所质押的公司股份不存在平仓风险， 质押风险在可控范围之内。 2、公司将持续关注股东所持有公司股份解押、质押情况，严格遵守相关规 定，及时履行信息披露义务，敬请投资者注意投资风险。 四、备查文件 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 安徽华人健康医药股份有限公司（以下简称"公司"）近日收到公司股东合 肥时达股权投资合伙企业（有限合伙）（以下简称"时达投资"）的通知，获悉 时达投资将其持有的部分公司股份进行了解除质押，相应的解除质押登 ...

Group 1 - The core viewpoint of the news is that Huaren Health's stock performance and financial metrics indicate a mixed outlook, with notable fluctuations in financing activities and shareholder dynamics [1][2][3] Group 2 - On February 26, Huaren Health's stock fell by 1.69%, with a trading volume of 241 million yuan. The financing buy-in amount was 18.06 million yuan, while the financing repayment was 18.36 million yuan, resulting in a net financing outflow of 305,500 yuan [1] - As of February 26, the total financing and securities lending balance for Huaren Health was 141 million yuan, with the financing balance accounting for 4.89% of the circulating market value, indicating a high level compared to the past year [1] - The company primarily engages in pharmaceutical agency, retail, and terminal procurement, with its main business revenue composition being 97.60% from traditional Chinese and Western medicines and 2.40% from other sources [1] - As of September 30, the number of Huaren Health shareholders was 20,100, a decrease of 22.86% from the previous period, while the average circulating shares per person increased by 29.64% to 7,422 shares [2] - For the period from January to September 2025, Huaren Health reported a revenue of 3.892 billion yuan, representing a year-on-year growth of 19.06%, and a net profit attributable to shareholders of 157 million yuan, up 45.21% year-on-year [2] - After its A-share listing, Huaren Health has distributed a total of 80.02 million yuan in dividends [3] - As of September 30, 2025, Hong Kong Central Clearing Limited was the fifth-largest circulating shareholder of Huaren Health, holding 2.3203 million shares, an increase of 1.3357 million shares from the previous period [3]

Group 1 - The core point of the article is that Huaren Health announced the release of restricted shares, with a total of 250,837,347 shares being released, which accounts for 62.71% of the total share capital [1] - The release of restricted shares will take effect on March 2, 2026, after which the proportion of restricted shares in circulation will decrease to 42.76%, while the proportion of unrestricted shares will increase to 57.24% [1] - The sponsor, Huatai United Securities, believes that the release of these restricted shares complies with relevant requirements and that the shareholders applying for the release have strictly fulfilled their commitments [1]

证券代码：301408 证券简称：华人健康 公告编号：2026-005 安徽华人健康医药股份有限公司 关于首次公开发行前已发行股份上市流通提示性 公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次上市流通的限售股份为安徽华人健康医药股份有限公司（以下简称 "公司""发行人"或"华人健康"）首次公开发行前已发行的限售股份。 2、本次申请解除限售的股东数量共计 6 户，解除限售股份的数量为 250,837,347 股，占公司总股本比例为 62.71%，限售期为自公司首次公开发行股 票并上市之日起 36 个月。 3、本次解除限售股份的上市流通日期为 2026 年 3 月 2 日（星期一）（因 2026 年 3 月 1 日为非交易日，上市流通日顺延至 2026 年 3 月 2 日）。 一、首次公开发行前已发行股份概况 经中国证券监督管理委员会《关于同意安徽华人健康医药股份有限公司首次 公开发行股票注册的批复》（证监许可[2022]2406 号）同意注册，公司获准向 社会公众发行人民币普通股（A 股）6,001.00 万股，并于 2023 年 3 ...

华泰联合证券有限责任公司关于 安徽华人健康医药股份有限公司首次公开发行前已发行股 份上市流通的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合证券"或"保荐人"）作 为安徽华人健康医药股份有限公司（以下简称"华人健康"或"公司"）首次公 开发行股票并在创业板上市持续督导阶段的保荐人，根据《证券发行上市保荐业 务管理办法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司 自律监管指引第 2 号——创业板上市公司规范运作》及《深圳证券交易所上市公 司自律监管指引第 13 号——保荐业务》等有关规定，对华人健康首次公开发行 前已发行股份上市流通的事项进行了核查，具体情况如下： 核查意见 1 核查意见 自公司首次公开发行股票上市之日至本核查意见出具日，公司未发生因股份 增发、回购注销、派发股票股利或资本公积金转增等导致股本数量变化的情况。 截至本核查意见出具日，公司总股本为 400,010,000 股，其中有限售条件流 通股为 250,838,697 股，占公司总股本比例为 62.71%，无限售条件流通股 149,171,303 股，占公司总股本比例为 37.29%。 一、首次公开发行前已发行股份概 ...

Group 1 - The core viewpoint of the news is that Huaren Health's stock experienced a decline of 2.80% on February 13, with a trading volume of 218 million yuan, indicating a negative trend in investor sentiment [1] - On February 13, Huaren Health had a financing buy-in amount of 11.82 million yuan and a financing repayment of 24.03 million yuan, resulting in a net financing outflow of 12.21 million yuan [1] - As of February 13, the total margin balance for Huaren Health was 148 million yuan, which represents 5.01% of its market capitalization, indicating a relatively high level of financing [1] Group 2 - As of September 30, Huaren Health had 20,100 shareholders, a decrease of 22.86% from the previous period, while the average number of circulating shares per person increased by 29.64% to 7,422 shares [2] - For the period from January to September 2025, Huaren Health reported a revenue of 3.892 billion yuan, reflecting a year-on-year growth of 19.06%, and a net profit attributable to shareholders of 157 million yuan, which is a 45.21% increase year-on-year [2] - Since its A-share listing, Huaren Health has distributed a total of 80.02 million yuan in dividends [3]

Group 1: Stock Price Movement - The stock price of Huaren Health (301408) experienced a decline of 4.05% to 20.83 yuan following a share reduction announcement by major shareholder Sequoia Capital, which plans to reduce up to 8 million shares (2% of total shares) between February 5 and April 30, 2026 [1] - On February 5, 2026, the first day of the reduction plan, 104,700 shares (0.0262% of total shares) were sold [1] Group 2: Financial Position - As of February 10, 2026, Huaren Health's financing balance stood at 168 million yuan, accounting for 5.49% of its market capitalization, which is above the 80th percentile of the past year [2] - The margin balance was 359,800 yuan, exceeding the 90th percentile of the past year, indicating a high level of market activity [2] Group 3: Recent Stock Performance - For the week ending February 6, 2026, Huaren Health's stock price fell by 3.95%, with a net outflow of 120 million yuan from major funds [3] - On February 9, 2026, the stock saw an intraday increase of 2.13% to 20.63 yuan, but still experienced a net outflow of 14.65 million yuan from major funds [3] - Year-to-date, the stock price has increased by 11.15%, with a 60-day increase of 30.32%, indicating significant volatility [3]

Core Viewpoint - The company, Anhui Huaren Health Pharmaceutical Co., Ltd., is focusing on enhancing its strategic partnerships and technological advancements in the healthcare sector, particularly through AI applications and e-commerce platforms [2][3]. Group 1: Company Developments - On October 23, 2025, the company established a strategic partnership with iFlytek Medical to enhance professional service efficiency in pharmacies and address user health needs through the launch of the "Pharmacy AI Health Assistant" [2]. - The company is actively investing in information technology to transition from information-based to intelligent integration, exploring suitable business scenarios for AI applications, which have improved service efficiency and customer experience [2]. - As of September 30, 2025, the company reported a revenue of 3.892 billion yuan, a year-on-year increase of 19.06%, and a net profit attributable to shareholders of 157 million yuan, reflecting a growth of 45.21% [8]. Group 2: Shareholder and Market Information - As of September 30, 2025, the company had 20,100 shareholders, a decrease of 22.86% from the previous period, with an average of 7,422 circulating shares per person, an increase of 29.64% [8]. - Alibaba Health is the second-largest shareholder, holding 7.51% of the company's shares, and the company collaborates with various Alibaba platforms, including Alipay and Tmall [3]. - The company has diversified its e-commerce presence, expanding its operations on major platforms such as JD.com, Pinduoduo, and Meituan, achieving significant growth during the reporting period [2].

Core Viewpoint - The company, Anhui Huaren Health Pharmaceutical Co., Ltd., is actively engaging in strategic partnerships and technological advancements in the healthcare sector, particularly focusing on AI applications and e-commerce platforms to enhance service efficiency and user experience. Group 1: Company Developments - On October 23, 2025, the company established a strategic partnership with iFlytek's medical division to enhance professional service efficiency in pharmacies through the launch of the "Pharmacy AI Health Assistant" [2] - The company is investing in information technology to transition from digitalization to intelligent integration, exploring AI applications in medical services and customer experience [2] - As of September 30, 2025, the company reported a revenue of 3.892 billion yuan, a year-on-year increase of 19.06%, and a net profit of 157 million yuan, up 45.21% year-on-year [8] Group 2: Shareholder and Market Information - As of September 30, 2025, the number of shareholders decreased by 22.86% to 20,100, while the average number of circulating shares per person increased by 29.64% to 7,422 shares [8] - The company has a significant shareholder relationship with Alibaba Health, which holds 7.51% of the company's shares, and collaborates with various Alibaba platforms [3] - The company has diversified its e-commerce presence across major platforms, including JD.com, Pinduoduo, and Meituan, achieving substantial growth during the reporting period [2]

Core Viewpoint - The company, Huaren Health, has shown fluctuations in its stock performance and financing activities, indicating a high level of trading activity and potential investor interest in the healthcare sector [1][2]. Group 1: Stock Performance - On February 10, Huaren Health's stock fell by 0.77%, with a trading volume of 198 million yuan [1]. - The financing buy-in amount for Huaren Health on the same day was 16.81 million yuan, while the financing repayment was 20.47 million yuan, resulting in a net financing outflow of 3.66 million yuan [1]. - As of February 10, the total financing and securities lending balance for Huaren Health was 169 million yuan, with the financing balance accounting for 5.49% of the circulating market value, indicating a high level compared to the past year [1]. Group 2: Financial Performance - For the period from January to September 2025, Huaren Health reported a revenue of 3.892 billion yuan, representing a year-on-year growth of 19.06% [2]. - The net profit attributable to the parent company for the same period was 157 million yuan, reflecting a significant year-on-year increase of 45.21% [2]. Group 3: Shareholder and Dividend Information - As of September 30, 2025, the number of shareholders for Huaren Health was 20,100, a decrease of 22.86% from the previous period [2]. - The company has distributed a total of 80.02 million yuan in dividends since its A-share listing [3]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited held 2.3203 million shares, an increase of 1.3357 million shares compared to the previous period [3].